The amount of the drug has been practically non-existent lately.”Ozempic» which are sold by the company pharmaciesAccording to the Panhellenic Pharmaceutical Association.

Thus, the available quantities are not enough to meet the ever-increasing demand and formulation.

“Despite the implementation of therapeutic protocols and despite the inclusion of a specific drug in the list of prohibited exports and its exclusive prescription only by electronic prescription, everything indicates that in this particular case the measures taken are unsatisfactory,” the PFS notes.

He suggests “additionally checking doctors for the possibility of issuing false conclusions, as a result of which therapeutic protocols are bypassed and approved indications for prescribing the drug are not observed only in patients with type 2 diabetes. that it is ultimately prescribed for weight control, and this is confirmed by many users of the drug.

It also makes the prospect of enrolling new patients with the drug under consideration uncertain and problematic, as PFS reports, when there is indeed a need based on the use of therapeutic protocols.

According to PFS, all this distortion of drug availability is dragging on and creates a huge problem in drugs belonging to the broader therapeutic category of DM (Trulicity, Saxenda, Victoza, etc.).

In addition, a serious public health problem arises for those patients who have already started long-term treatment with these drugs, since the lack of supply on the market makes their continuation of the therapeutic regimen doubtful.

The PFC asks “finally, that control mechanisms work in all directions to ensure the rational use of drugs in this particular category, based on approved indications and protocols. Finally, the EOF should check the companies in question to establish domestic coverage.”

News today

Subscribe to kathimerini.gr on Google News and be the first to know all the news

See all the latest news from Greece and the world at kathimerini.gr